HK1165547A1 - 內皮抑制素作為心力衰竭標記的應用 - Google Patents

內皮抑制素作為心力衰竭標記的應用

Info

Publication number
HK1165547A1
HK1165547A1 HK12105510.6A HK12105510A HK1165547A1 HK 1165547 A1 HK1165547 A1 HK 1165547A1 HK 12105510 A HK12105510 A HK 12105510A HK 1165547 A1 HK1165547 A1 HK 1165547A1
Authority
HK
Hong Kong
Prior art keywords
endostatin
marker
heart failure
heart
failure
Prior art date
Application number
HK12105510.6A
Other languages
English (en)
Inventor
Ursula-Henrike Wienhues-Thelen
Dirk Block
Hendrik Huedig
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1165547A1 publication Critical patent/HK1165547A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12105510.6A 2009-04-27 2012-06-06 內皮抑制素作為心力衰竭標記的應用 HK1165547A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005801 2009-04-27
PCT/EP2010/002513 WO2010124821A1 (en) 2009-04-27 2010-04-23 Use of endostatin as a marker of heart failure

Publications (1)

Publication Number Publication Date
HK1165547A1 true HK1165547A1 (zh) 2012-10-05

Family

ID=41134573

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105510.6A HK1165547A1 (zh) 2009-04-27 2012-06-06 內皮抑制素作為心力衰竭標記的應用

Country Status (8)

Country Link
US (1) US20120009610A1 (zh)
EP (1) EP2425245B1 (zh)
JP (1) JP2012524282A (zh)
CN (1) CN102422157B (zh)
CA (1) CA2756120C (zh)
ES (1) ES2607491T3 (zh)
HK (1) HK1165547A1 (zh)
WO (1) WO2010124821A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2769227B1 (en) 2011-10-17 2016-07-27 Roche Diagnostics GmbH Troponin and bnp based diagnosis of risk patients and cause of stroke
CA2883890C (en) 2012-09-12 2021-11-09 Dirk Block Identification of patients with abnormal fractional shortening
EP3399315A3 (en) * 2012-12-04 2019-01-02 Roche Diagnostics GmbH Biomarkers in the selection of therapy of heart failure
EP3441768A3 (en) * 2013-08-26 2019-03-20 Roche Diagnostics GmbH Marker for statin treatment stratification in heart failure
EP3470848A3 (en) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
ES2676553T3 (es) 2014-03-26 2018-07-20 F. Hoffmann-La Roche Ag IGFBP7 para el diagnóstico de la disfunción diastólica
WO2016066698A1 (en) * 2014-10-29 2016-05-06 Roche Diagnostics Gmbh Biomarkers for risk prediction of mortality
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
GB201912856D0 (en) * 2019-09-06 2019-10-23 Nordic Bioscience As Assay for assessing heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005236075A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
EP1967853B1 (en) * 2007-03-06 2010-01-27 Roche Diagnostics GmbH Use of Nogo-C in the assessment of heart failure
JP5045906B2 (ja) * 2007-06-26 2012-10-10 国立大学法人山口大学 新規虚血マーカー及びこれを用いた虚血状態の検出方法
WO2009040133A1 (en) * 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法

Also Published As

Publication number Publication date
CN102422157B (zh) 2014-10-29
US20120009610A1 (en) 2012-01-12
WO2010124821A1 (en) 2010-11-04
CN102422157A (zh) 2012-04-18
ES2607491T3 (es) 2017-03-31
JP2012524282A (ja) 2012-10-11
CA2756120C (en) 2022-08-30
EP2425245A1 (en) 2012-03-07
CA2756120A1 (en) 2010-11-04
EP2425245B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
HK1165547A1 (zh) 內皮抑制素作為心力衰竭標記的應用
EP2393914A4 (en) LUNG TISSUE ENGINEERING
PL2480218T3 (pl) Kapsułki odporne na kwas
EP2408400A4 (en) RECONFIGURATION OF CARDIAC CHARACTERISTICS
IL222888A0 (en) Anchored cardiac ablation catheter
EP2506888A4 (en) Total artificial heart
EP2391979A4 (en) TRACKING OF FABRICS
GB0907874D0 (en) Skin marker
EP2502068A4 (en) URINARY TRIAOSYLCERAMIDE (GB3) AS A MARKER OF CARDIAC DISEASE
HK1166130A1 (zh) 作為癌症標誌物的應用
EP2478927A4 (en) CATHETER
PL2506733T3 (pl) Podeszwa
GB0907222D0 (en) Pressure joint
EP2448627A4 (en) SAFETY CATHETER
HK1167092A1 (zh) 用作藥物的能夠恢複肌肉強度的修飾的聚集蛋白片段
GB2475743B (en) Balloon catheter
GB0908071D0 (en) Marker
HK1169314A1 (zh) δ-生育酚-碳水化合物作為脫色劑的用途
HK1165204A1 (zh) 作為肺癌標誌物的
GB0921060D0 (en) Catheter
GB0905964D0 (en) Marker
ZA201106839B (en) A heart valve
IL218326A0 (en) Use of cathepsin h
EP2467494A4 (en) PON1 AS A MARKER FOR HEART FAILURE
GB0917974D0 (en) A walking staff